Researchers at the Sylvester Comprehensive Cancer Center have identified a therapeutic target in pancreatic cancer, demonstrating how blocking IL1RAP disrupts inflammatory signaling and protective tumor networks. The discovery is now advancing toward a neoadjuvant clinical trial combining targeted therapy with chemoimmunotherapy in operable pancreatic cancer patients before surgery.
Pancreatic cancer continues to present formidable clinical challenges, largely because tumors are embedded in a complex microenvironment that shields them from both conventional chemotherapy and modern immunotherapy. While recent therapeutic advances have extended survival in metastatic settings, bringing those gains to patients with operable tumors remains a protracted challenge. A new study published in JCI Insight examines how specific signaling networks sustain this resilience, offering a pathway toward breaking down the tumor’s defenses.
Targeting the IL1RAP Control Point
The research centers on IL1RAP, a receptor that functions as a critical node in inflammatory signaling. Investigators found that this receptor helps coordinate the web of surrounding cells—including fibroblasts and immune cells—that support tumor growth and treatment resistance.
By acting as a shared control point for multiple inflammatory cues, IL1RAP helps maintain an inflamed but immune-suppressed state within the tumor microenvironment. This duality explains why standard therapies frequently fail: the inflammation drives disease progression while suppressing the immune system’s capacity to mount a counterattack.
"When we target IL1RAP, we are blocking a shared ‘helper’ receptor that many inflammatory signals rely on to transmit their message," said Datta, a pancreatic and hepatobiliary surgical oncologist, co-leader of the Gastrointestinal Site Disease Group at Sylvester, and senior author of the study.
Preclinical Shifts in the Tumor Microenvironment
In preclinical evaluations, inhibiting IL1RAP altered the composition and behavior of the tissue surrounding the cancer. The Sylvester team observed that immune-suppressive cells dropped in abundance, while T cells grew more active and functionally capable. Furthermore, the treated tumors developed less fibrosis and demonstrated stronger responses to combination treatment.
Rather than attempting to kill malignant cells directly through cytotoxicity alone, this therapeutic strategy focuses on dismantling the structural architecture that protects them. Disrupting the microenvironment allows existing drugs to penetrate and operate with greater efficacy.
Advancing to a Neoadjuvant Clinical Trial
Translating these laboratory findings into human care, the Sylvester Comprehensive Cancer Center is launching a neoadjuvant clinical trial. The study will evaluate IL1RAP-targeted treatment combined with chemoimmunotherapy in patients diagnosed with operable pancreatic cancer prior to surgical resection.
Administering the regimen before surgery gives researchers an unusual observational window. Clinicians can examine tumor tissue before and after intervention, mapping exactly how individual cancer biology shifts in response to therapy.
"This trial gives us a unique window to connect the science directly to patient outcomes, which is essential for moving the field forward."
Broader Mechanisms of Immune Evasion
Parallel insights into pancreatic cancer evasion come from separate findings shared by Sanford Burnham Prebys Medical Discovery Institute researchers, highlighting how malignant cells construct protective safe zones. Cosimo Commisso, Professor and Deputy Director, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, shared on LinkedIn regarding work by Icahn School of Medicine at Mount Sinai researchers that pancreatic cancer cells use two specific proteins to build ‘safe zones’ around themselves, recruiting immune cells that shield the tumor and keep cancer-fighting cells out. According to work detailed by Icahn School of Medicine at Mount Sinai researchers, including authors Chiara Falcomatà, Maximilian M. Schaefer, Bhavya Singh, Divya Chhamalwan, Alexander Tepper, Sebastian R. Nielsen, Hunter T. Potak, Maxime Dhainaut, Gurkan Mollaoglu, Matthew D. Park, Miriam Merad, Alessia Baccarini, and Brian D. Brown in a study titled ‘A serpin–myeloid axis in pancreatic cancer heterogeneity and immune evasion’, malignant cells deploy specific proteins to recruit immune cells that physically shield the tumor from cancer-fighting cells.
Blocking those proteins in murine models rendered tumors more vulnerable to immunotherapy, reinforcing the broader scientific consensus that targeting tumor microenvironments and structural shields is essential for treating this malignancy.
Financial backing for the Sylvester translational effort is provided by a Translational Research Grant from the V Foundation, awarded following a national peer-review process. As the upcoming clinical trial gets underway, researchers will determine whether disrupting these inflammatory and protective networks translates into durable survival benefits for patients facing operable pancreatic cancer.
